Aerosol Delivery Devices Market Report 2024

The aerosol delivery devices market size has grown strongly in recent years. It will grow from $44 billion in 2023 to $47.6 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historical period was driven by several factors including the rising incidence of respiratory diseases, regulatory clearances, increased adoption of portable devices, higher healthcare spending, awareness campaigns promoting respiratory health, governmental initiatives, and funding.

The aerosol delivery devices market size is expected to see strong growth in the next few years. It will grow to $65.48 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. Anticipated growth in the forecast period will be fueled by expanding applications in managing chronic diseases, greater investments in research and development (R&D), growing demand for personalized medicine, increased air pollution causing respiratory disorders, and a growing elderly population demanding respiratory treatments. Key trends in this period include technological advancements, improvements in drug delivery systems, introduction of generic alternatives, development of biologics and specialty drugs for inhalation therapy, and advancements in nanotechnology for aerosol drug delivery.

The rising incidence of respiratory diseases is anticipated to drive growth in the aerosol delivery device market. These diseases encompass various conditions affecting the airways, lungs, and respiratory system, attributed to factors such as air pollution, smoking, allergens, and respiratory infections. Aerosol delivery devices play a crucial role in treating respiratory diseases by efficiently administering medications such as bronchodilators and corticosteroids directly to the lungs, thereby enhancing therapeutic outcomes and patient compliance. According to data from the National Center for Health Statistics (NCHS) in May 2024, the prevalence of current asthma among adults in the United States increased from 8% in 2021 to 8.7% in 2022, with a corresponding rise in asthma episodes from 3.3% to 3.7% within the same period. Consequently, the growing prevalence of respiratory diseases is expected to propel the aerosol delivery device market forward.

Key players in the aerosol delivery device market are concentrating on developing innovative inhaler dose trackers to enhance medication adherence through user-friendly designs. These intelligent trackers, equipped with sensors and connectivity features, monitor medication usage in real-time, improving adherence and providing comprehensive data to patients and healthcare providers. For instance, in June 2024, Aseptika Ltd., a UK-based MedTech company, introduced the PUFFClicker3 Universal Inhaler, a pioneering smart inhaler dose counter compatible with various inhalers. It employs sensors to record each dose, offers real-time monitoring, features a user-friendly interface, and utilizes Bluetooth connectivity to sync with health apps. This innovation assists patients in adhering to medication schedules while equipping healthcare providers with valuable adherence information.

In January 2024, Kindeva Drug Delivery, a pharmaceutical company based in the United States, acquired Summit Biosciences Inc. for an undisclosed sum. This acquisition is intended to broaden Kindeva's portfolio in drug delivery technologies, with a specific focus on sterile drug products and nasal spray devices. By integrating Summit Biosciences, Kindeva aims to strengthen its market position and enhance its technological capabilities in these specialized areas. Summit Biosciences Inc., also based in the US, specializes in manufacturing aerosol delivery devices, including nasal sprays.

Major companies operating in the aerosol delivery devices market are Pfizer Inc, Merck & Co Inc, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), 3M Company, Becton Dickinson and Company, Koninklijke Philips NV, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Draegerwerk AG & Co KGaA, Shionogi & Co Ltd, Hikma Pharmaceuticals PLC, Chiesi Farmaceutici SpA, Vectura Group plc, Fresenius Kabi AG, Metall Zug AG, Sunovion Pharmaceuticals Inc., Omron Healthcare, Inc., PARI GmbH, Aerogen Inc, Clement Clarke International Ltd, Iconovo AB.

North America was the largest region in the aerosol delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aerosol delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the aerosol delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aerosol delivery devices are specialized medical tools designed to administer medication as a mist or aerosol directly into the lungs. These devices are essential for treating respiratory conditions by precisely delivering therapeutic agents. Their primary goal is to ensure the effective and targeted distribution of medication within the respiratory system.

There are several types of aerosol delivery devices available, including dry powder inhalers, measured-dose inhalers, and nebulizers. Dry powder inhalers release medication in a powdered form, activated by the user's breath, and are utilized for conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other non-respiratory ailments. These devices are typically distributed through retail pharmacies, hospital pharmacies, and e-commerce platforms.

The aerosol delivery devices market research report is one of a series of new reports that provides aerosol delivery devices market statistics, including aerosol delivery devices industry global market size, regional shares, competitors with an aerosol delivery devices market share, detailed aerosol delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the aerosol delivery devices industry. This aerosol delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aerosol delivery devices market consists of sales of soft mist inhalers, spacer devices, breath-actuated inhalers, and topical spray bottles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.